Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

Oaknin et al. (Sat,) studied this question.

www.synapsesocial.com/papers/69d786ad3fae90fd6048f93f — DOI: https://doi.org/10.1136/jitc-2021-003777

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer· 2020 · 352 citations
2. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance· 2019 · 2,212 citations
3. Integrated genomic characterization of endometrial carcinoma· 2013 · 5,751 citations
4. Activity of durvalumab in advanced endometrial cancer (AEC) according to mismatch repair (MMR) status: The phase II PHAEDRA trial (ANZGOG1601).· 2019 · 55 citations
5. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade· 2017 · 6,578 citations